Join us for our March LIVE webinars on metastatic colorectal cancer & hepatocellular carcinoma. In each broadcast, a pair of experts will speak LIVE on the pressing topics of diagnosis, treatment, and outcome. RSVP today to both!

General Discussions

Axi-Cel Efficacy Persists at 2-Year Assessment for Large B-Cell Lymphoma

By Silas Inman
PUBLISHED WEDNESDAY, DECEMBER 31, 1969
Axicabtagene ciloleucel (axi-cel) elicited a 2-year overall survival (OS) rate of 51% in patients with refractory large B cell lymphoma, representing a clear plateau in the survival curve, according to long-term findings from the ZUMA-1 trial presented at the 2018 ASH Annual Meeting and published in Lancet Oncology.1,2

At a median follow-up of 27.1 months, the 24-month progression-free survival (PFS) rate was 39% with the CD19-targeted CAR T-cell therapy. The median PFS was 5.9 months. Moreover, 39% of patients continued to have an ongoing response, with a median duration of response that was not yet reached for those who achieved a complete remission (CR). Additionally, the median OS was not yet reached.

"This 2-year assessment demonstrates that axi-cel can induce durable remissions in a substantial proportion of patients with an acceptable long-term safety profile," lead investigator Sattva Neelapu, MD, professor of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, said in a statement. "There also is evidence of gradual B-cell recovery in most patients with refractory large B-cell lymphoma who otherwise have limited treatment options."

In October 2017, the FDA approved axi-cel as a treatment for adults with relapsed or refractory NHL, based on findings from the ZUMA-1 trial. The study evaluated 108 patients, consisting of 101 from the phase II portion of the trial and 7 from the phase I group. In phase II, patients were enrolled into 2 cohorts consisting of those with diffuse large B-cell lymphoma (DLBCL; n = 77) and those with primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL transformed from follicular lymphoma (TFL; n = 24).

Prior to infusion of axi-cel, a conditioning regimen of fludarabine (30 mg/m2) and cyclophosphamide (500 mg/m2) was administered for 3 days. Axi-cel was administered as a single infusion of modified autologous T cells at a target dose of 2 x 106 CAR-positive T cells/kg. The treatment was manufactured successfully for 99% of patients, and 91% of patients received treatment with the CAR T-cell therapy.

The best achieved objective response rate (ORR) with axi-cel was 83% by investigator assessment and 74% by central review, with CR rates of 58% and 54%, respectively. At this analysis, 39% of patients continued to respond to therapy by investigator assessment and 36% were still responding by central review. Overall, 93% of those in response at month 12 continued to respond at 24 months.

In those with double expresser or high-grade B cell lymphoma (n = 37), the ORR was 91% and the CR rate was 70%. Overall, 48% of these patients continued to respond to therapy at the analysis.

CAR-positive T cells persisted over time in patients with ongoing responses. At the 24-month assessment, 66% of patients in response continued to have detectable CAR gene-marked T cells. B cell aplasia resolved by month 9 for most patients, with 61% having detectable B cells in the blood. By month 24, 75% of patients had detectable B cells. Overall, 31% of patients required intravenous immunoglobulins.

The investigators noted that there were no new cases of cytokine release syndrome or neurotoxicity reported following the 1-year follow-up analysis. Other grade 3/4 events did manifest, however, including grade 3 mental status change, grade 4 myelodysplastic syndrome, grade 3 lung infection, and 2 grade 3 bacteremia events. None of these events were determined to be related to axi-cel.

Grade ≥3 treatment-emergent cytopenia occurred in 86% of patients, including neutropenia (80%), thrombocytopenia (40%), and anemia (45%). There were significantly fewer cytopenias present on or after 3 months (grade ≥3 events occurred in 17% of patients).

References

  1. Neelapu SS, Ghobadi A, Jacobson CA, et al. 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma. Proceedings from the 2018 ASH Annual Meeting and Exposition; December 1 to 4, 2018; San Diego, California. Abstract 2967.
  2. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial [published online ahead of print, December 2, 2018]. Lancet Oncol. doi:10.1016/S1470-2045(18)30864-7
This article originally appeared on OncLive® as “Axi-Cel Efficacy Persists at 2-Year Assessment for Large B-Cell Lymphoma.”



 
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.